Market Analysis and Price Projections for the Drug NDC: 68462-0135
Introduction
When analyzing the market and projecting prices for a specific drug, such as Abiraterone Acetate with the NDC 68462-0135, it is crucial to consider various factors including current market trends, regulatory environments, and industry predictions.
Drug Overview
Abiraterone Acetate, with the NDC 68462-0135, is a medication used primarily in the treatment of prostate cancer. It is manufactured by Glenmark Pharmaceuticals Inc., USA[2].
Current Market Trends
Price Fluctuations
Recent data shows that the price per unit of Abiraterone Acetate 250 MG tablets has fluctuated over the past few months. As of December 18, 2024, the price per unit was $1.07554, which is slightly lower than the $1.08623 recorded on November 20, 2024, and higher than the $0.98375 on October 23, 2024[2].
Vendor Pricing
Glenmark Pharmaceuticals Inc., USA, offers this drug in a pack of 120 tablets, with a total price of $224.95, translating to a price per unit of $1.87458. This pricing is under the Federal Supply Schedule (FSS) and is valid from October 15, 2022, to October 14, 2027[2].
Regulatory Environment
Transparency and Reporting
The pharmaceutical industry is increasingly subject to transparency requirements, as seen in the Prescription Drug Price Transparency Act in Oregon. This act mandates pharmaceutical manufacturers to report on drug prices, including new prescriptions costing more than $670 a month, and the reasons for price increases. Such transparency helps in understanding the factors influencing drug prices, such as rebates, co-pay assistance programs, and research and development costs[5].
Affordability and Pricing Controls
There are ongoing discussions and recommendations to implement upper payment limits for certain drugs to control affordability. This includes leveraging bulk purchasing and state-contracted manufacturing to reduce costs. However, the effectiveness of such measures is still being evaluated[4].
Industry Predictions for 2025
Role of Artificial Intelligence (AI)
Industry experts predict a significant increase in the adoption of AI in clinical development and data science models. AI will be used more extensively to address complex topics such as the probability of technical and regulatory success (PTRS) and to retrieve information on specific landscapes or indications. This could impact how drug prices are analyzed and projected[3].
External Data and AI Models
The use of reliable external data to train internal data science models, including large language models (LLMs), is expected to grow. This trend could enhance the accuracy of price projections by incorporating more diverse and reliable data sources[3].
Price Projections
Short-Term Projections
Given the recent price fluctuations, it is likely that the price per unit of Abiraterone Acetate will continue to vary slightly in the short term. However, the overall trend suggests stability around the $1.00 to $1.10 per unit range.
Long-Term Projections
In the long term, several factors could influence price projections:
- Regulatory Changes: Implementations of upper payment limits or bulk purchasing models could reduce prices.
- Market Competition: Increased competition from generic or biosimilar drugs could lower prices.
- AI and Data Trends: Improved data analysis through AI could lead to more efficient pricing strategies, potentially stabilizing or reducing prices.
Key Factors Influencing Drug Prices
Rebates and Discounts
Rebates and discounts play a significant role in the final price of prescription drugs. These can vary widely and are often negotiated between manufacturers, wholesalers, and payers[5].
Research and Development Costs
Manufacturers often attribute price increases to research and development costs, as well as obligations to shareholders[5].
Supply Chain Transparency
Understanding the interactions and financial negotiations within the pharmaceutical supply chain is crucial for accurate price projections. Transparency across the supply chain can help identify cost factors such as markups, fees, and incentive programs[4].
Conclusion
The market analysis and price projections for Abiraterone Acetate with the NDC 68462-0135 indicate a stable but slightly fluctuating price trend in the short term. Long-term projections are influenced by regulatory changes, market competition, and the integration of AI in data analysis. Understanding these factors is essential for making informed decisions in the pharmaceutical industry.
Key Takeaways
- Current Prices: The price per unit of Abiraterone Acetate 250 MG tablets has been around $1.00 to $1.10.
- Regulatory Environment: Transparency and potential pricing controls could impact future prices.
- AI and Data Trends: Increased use of AI and external data is expected to enhance price projection accuracy.
- Supply Chain Transparency: Understanding the pharmaceutical supply chain is crucial for accurate price projections.
FAQs
Q1: What is the current price per unit of Abiraterone Acetate 250 MG tablets?
A1: As of December 18, 2024, the price per unit is $1.07554[2].
Q2: Who manufactures Abiraterone Acetate with the NDC 68462-0135?
A2: Glenmark Pharmaceuticals Inc., USA, manufactures this drug[2].
Q3: What are the key factors influencing the price of prescription drugs?
A3: Key factors include rebates, discounts, research and development costs, and supply chain transparency[5].
Q4: How might AI impact drug price projections in 2025?
A4: AI is expected to enhance data analysis and accuracy in price projections, particularly through the use of large language models (LLMs) and external data[3].
Q5: What regulatory measures are being considered to control drug prices?
A5: Measures include implementing upper payment limits, bulk purchasing, and state-contracted manufacturing to reduce costs[4].
Sources
- DrugPatentWatch - Latest drug prices and trends for NDC 68462-0135.
- DrugPatentWatch - Latest pharmaceutical drug prices and trends for NDC 68462-0135.
- Intelligencia.ai - 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch.
- Oregon Department of Consumer and Business Services - Prescription Drug Price Transparency Results and Recommendations.
- Oregon Department of Consumer and Business Services - Prescription Drug Price Transparency Annual Report 2019.
